Suven Life receives 2 patents for CNS drug in US & New Zealand

Suven Life Sciences Ltd has secured patents in US and New Zealand for one of its new chemical entities (NCEs) used for CNS therapy through new mechanism of action – H3 Inverse agonist. The patents in US and New Zealand are valid until 2030 and 2031 respectively. The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.
 
Histaminargic dysfunction has been strongly associated with the cognitive and behavioural deficits observed in several CNS disorders. H3 receptor blockade elevates acetylcholine in brain regions responsible for cognition, thus offer a means for targeting cognitive processes. Novel, potent, selective, brain penetrant and orally active H3 receptor inverse agonist for the treatment of cognitive deficits would offer new line of treatment for this unmet medical need.
 
With these new patents, Suven has a total of 20 granted patents from USA and 23 granted patents from New Zealand. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.
 
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO, Suven.